Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Medinger

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Anticancer Research|September 29, 2020
Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation - A Single Centre StudyUrsina Studer, Nina Khanna, Karoline Leuzinger, et al.
Bone Marrow Transplantation|April 21, 2023
Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with BusulfanClaire Seydoux, Chakradhara Rao Satyanarayana Uppugunduri, Michael Medinger, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2005
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursKlaus Mross, Joachim Drevs, Marianne Müller, et al.
European Journal of Applied Physiology|April 10, 2026
Cellular profile of hematopoietic stem cells mobilized by exercise versus G-CSF in healthy related donorsElias Siebold, Laura Infanti, Hans-Jürgen Gruber, et al.
Transplantation and Cellular Therapy|November 7, 2022
Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for MalignancySimone Dertschnig, Peter Gergely, Jürgen Finke, et al.
Annals of Hematology|October 24, 2020
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trialClaire Seydoux, Michael Medinger, Sabine Gerull, et al.
Annals of Hematology|September 19, 2020
Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantationBeatrice Drexler, Felicitas Zurbriggen, Tamara Diesch, et al.
Ejhaem|February 23, 2023
Allogeneic hematopoietic stem cell transplantation in non-Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is betterEkaterina Rebmann, Mitja Nabergoj, Bastien Grandjean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumorsJoachim Drevs, Patrizia Siegert, Michael Medinger, et al.
Transplantation and Cellular Therapy|December 11, 2023
Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCTKhalil Ben Hassine, Claire Seydoux, Sonia Khier, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Anticancer Research|September 29, 2020
Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation - A Single Centre StudyUrsina Studer, Nina Khanna, Karoline Leuzinger, et al.
Bone Marrow Transplantation|April 21, 2023
Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with BusulfanClaire Seydoux, Chakradhara Rao Satyanarayana Uppugunduri, Michael Medinger, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2005
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursKlaus Mross, Joachim Drevs, Marianne Müller, et al.
European Journal of Applied Physiology|April 10, 2026
Cellular profile of hematopoietic stem cells mobilized by exercise versus G-CSF in healthy related donorsElias Siebold, Laura Infanti, Hans-Jürgen Gruber, et al.
Transplantation and Cellular Therapy|November 7, 2022
Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for MalignancySimone Dertschnig, Peter Gergely, Jürgen Finke, et al.
Annals of Hematology|October 24, 2020
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trialClaire Seydoux, Michael Medinger, Sabine Gerull, et al.
Annals of Hematology|September 19, 2020
Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantationBeatrice Drexler, Felicitas Zurbriggen, Tamara Diesch, et al.
Ejhaem|February 23, 2023
Allogeneic hematopoietic stem cell transplantation in non-Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is betterEkaterina Rebmann, Mitja Nabergoj, Bastien Grandjean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumorsJoachim Drevs, Patrizia Siegert, Michael Medinger, et al.
Transplantation and Cellular Therapy|December 11, 2023
Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCTKhalil Ben Hassine, Claire Seydoux, Sonia Khier, et al.
Pageof 9